NovoCure Ltd Reports Financial Results for Quarter Ended June 30, 2026

What Happened
NovoCure Ltd announced financial results for the quarter ended June 30, 2026 by issuing a press release on July 23, 2026; the company filed an 8-K (Item 2.02) to disclose those quarterly results and attached the press release as Exhibit 99.1. The filing was executed by Chief Financial Officer Christoph Brackmann.

Key Details

• Filing date: July 23, 2026 (Form 8-K).
• Period reported: quarter ended June 30, 2026.
• Disclosure: press release announcing results attached as Exhibit 99.1 (dated July 23, 2026).
• Form sections: Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits); signed by CFO Christoph Brackmann.

Why It Matters
This 8-K signals NovoCure’s public release of its latest quarterly earnings information (revenue, earnings, and other quarterly results will be in the attached press release). Retail investors should review Exhibit 99.1 for the specific financial figures, any management commentary or guidance, and any changes to expectations that could affect the stock. Filing under Item 2.02 ensures the company has timely disclosed material operating and financial information to the market.